Brief: Pharmacyte Biotech Announces Submission Of Drug Master File To FDA For Co's Pancreatic Cancer Therapy
27/07/2020 14:16
July 27 (Reuters) - PharmaCyte Biotech Inc PMCB.PK :
* PHARMACYTE BIOTECH ANNOUNCES SUBMISSION OF DRUG MASTER
FILE TO
FDA FOR COMPANY’S PANCREATIC CANCER THERAPY
Source text for Eikon: ID:nBw2fH20Ja
Further company coverage: PMCB.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pharmacyte Biotech
See all newsBrief: Pharmacyte Biotech Inc - Increases Stake In Tnf Pharmaceuticals By $3 Million
Brief: PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease
Brief: Pharmacyte Biotech Acquires $5 Million Stake In Emerging Women’S Health Innovator Femasys
Brief: Femasys Inc. Secures Additional Financing With Strategic Investment From Investors Led By Pharmacyte Biotech
Brief: Pharmacyte Biotech Announces Final Results Of Tender Offer